Coya Therapeutics White Background.jpg
Coya Therapeutics Announces Peer-Reviewed Publication of its First-in-Class Regulatory T Cell-derived Exosomes and their Therapeutic Potential in Neurodegeneration and Inflammation Related Diseases
23 juin 2022 09h27 HE | Coya Therapeutics, Inc.
Regulatory T Cell (Treg)-derived exosome data have been published in the peer-reviewed journal Frontiers of Immunology Characterization of Treg-derived exosomes show Treg cells-conserved functional...
Coya Therapeutics White Background.jpg
Coya Therapeutics Secures Option Agreement for Exclusive Worldwide Rights to Exosome Engineering Technology from Carnegie Mellon University
15 juin 2022 09h27 HE | Coya Therapeutics, Inc.
Proprietary technology generates Exosome Polymer Hybrids (EPHs) which allow for efficient and versatile method of customizing cargoes of Treg-derived exosomes using oligonucleotide tethers ...
Coya Therapeutics White Background.jpg
Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T Cell Therapeutics
07 juin 2022 10h02 HE | Coya Therapeutics, Inc.
Coya Therapeutics’ clinical and biomarker data continue to demonstrate regulatory T cells (Tregs) ability to meaningfully dampen both systemic and neuroinflammation, thereby restoring the immune...
Vbl_Logo.png
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer
17 sept. 2021 07h00 HE | VBL Therapeutics
The OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date;Remains on track to complete enrollment in 1Q22 TEL...
Vbl_Logo.png
VBL Therapeutics to Present at Upcoming Conferences
10 sept. 2021 07h00 HE | VBL Therapeutics
TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd...
Vbl_Logo.png
VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility
30 août 2021 07h00 HE | VBL Therapeutics
U.S. FDA CMC clearance of VB-111 produced in Modiin, Israel facility an important milestone toward potential commercializationOVAL Phase 3 trial evaluating VB-111 in platinum resistant ovarian cancer...
CB2 Insights.jpg
CB2 Insights to Host Q1 2020 Earnings Call on July 15, 2020
08 juil. 2020 16h45 HE | CB2 Insights
TORONTO, July 08, 2020 (GLOBE NEWSWIRE) -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF), will be hosting its Q1 2020 earnings call on Wednesday, July 15, 2020 at 9:00 a.m....
Altasciences_Gradient_V_RGB.png
Dr. Joseph A. Francisco Appointed Chief Toxicologist at Altasciences
22 juin 2020 09h19 HE | Altasciences Company Inc.
LAVAL, Quebec, June 22, 2020 (GLOBE NEWSWIRE) -- Altasciences announced today the appointment of Dr. Joseph A. Francisco as Chief Toxicologist, effective June 22, 2020. Dr. Francisco is a...
CB2 Insights.jpg
VIVO and CB2 Insights Enter Technology and Research Partnership
29 oct. 2019 07h48 HE | CB2 Insights
Partnership to focus on implementing a medical product development strategy for VIVO’s global medical cannabis offering, utilizing CB2 Insights’ leading technology platform Sail and research...
Aldevron Names Diane Rogers as Senior Vice President Commercial Development
09 oct. 2019 15h46 HE | Aldevron
Fargo, North Dakota, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Diane Rogers has joined Aldevron as its Senior Vice President Commercial Development. In her role, Rogers will be responsible for leading the...